Autoimmunity as a Result of Escape from RNA Surveillance

Michael P. Bachmann, Holger Bartsch, Joanne K. Gross, Shannon M. Maier, Timothy F. Gross, Jennifer L. Workman, Judith A. James, A. Darise Farris, Bettina Jung, Claudia Franke, Karsten Conrad, Marc Schmitz, Cordula Böttner, Jill P. Buyon, Imre Semsei, John B. Harley and E. Peter Rieber

*J Immunol* 2006; 177:1698-1707; doi: 10.4049/jimmunol.177.3.1698
http://www.jimmunol.org/content/177/3/1698

**References**
This article cites 39 articles, 18 of which you can access for free at:
http://www.jimmunol.org/content/177/3/1698.full#ref-list-1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Autoimmunity as a Result of Escape from RNA Surveillance

Michael P. Bachmann,* Holger Bartsch,* Joanne K. Gross,† Shannon M. Maier,‡‡
Timothy F. Gross,‡ Jennifer L. Workman,† Judith A. James,‡‡ A. Darise Farris,‡‡
Bettina Jung,* Claudia Franke,* Karsten Conrad,* Marc Schmitz,* Cordula Büttner,*
Jill P. Buyon,§ Imre Semsei,¶ John B. Harley,†‡¶ and E. Peter Rieber*

In previous studies, we detected a frame shift mutation in the gene encoding the autoantigen La of a patient with systemic lupus erythematosus. The mutant La mRNA contains a premature termination codon. mRNAs that prematurely terminate translation should be eliminated by RNA quality control mechanisms. As we find Abs specific for the mutant La form in ~30% of sera from anti-La-positive patients, we expected that mutant La mRNAs circulate RNA control and the expression of mutant La protein could become harmful. Indeed, real-time PCR, immunostaining, and immunoblotting data of mice transgenic for the mutant La form show that mutant La mRNAs are not repressed in these animals and are translated to mutant La protein. In addition to the mutant La protein, we detected a minor portion of native human La in the mutant La-transgenic mice. Therefore, ribosomal frame shifting may allow the mutant La mRNA to escape from RNA control. Interestingly, expression of the mutant La mRNA results in a lupus-like disease in the experimental mice. Consequently, escape of mutant La mRNA from RNA control can have two effects: it 1) results in the expression of an immunogenic (neo)epitope, and 2) predisposes to autoimmunity. The Journal of Immunology, 2006, 177: 1698–1707.

Eukaryotes have evolved a RNA quality control mechanism which allows cells to identify and degrade mRNAs containing nonsense mutations. This process is known as nonsense-mediated decay (NMD) of mRNA or RNA surveillance (1, 2). Nonsense mutations usually result in premature termination codons (PTC). The role of NMD is to recognize such mutant forms of mRNAs, and to eliminate them as truncated mutant proteins could cause dominant-negative effects on the normal cellular function of the respective native protein. Only in rare cases do mRNAs with nonsense mutations escape NMD. In all of these instances, the poly(A) tail of the truncated proteins results in severe phenotypes. For example, the expression of mutant ROR2 mRNA leads to polydactyly, and expression of mutant forms of hemoglobin leads to β-thalassemias (3–5).

The core NMD machinery is phylogenetically conserved from yeast to humans. Depletion of upf1 in mice—a factor which is assumed to be involved in the recognition of a PTC—leads to embryonic death at the implantation stage (6). This implies the fundamental and vital role of the NMD mechanism.

At the molecular level, NMD is not yet fully understood. According to recent models, so-called exon junction complexes (EJCs) assemble at the splice junctions where they remain even after transport to the cytoplasm. During the first round of translation, these EJCs will be removed. If a mRNA contains a PTC, the ribosome does not pass all splice junctions and the EJCs downstream of the PTC will remain associated with the mutant mRNA. mRNAs containing EJCs after the initial round of translation will be degraded.

In previous studies, we prepared an expression cDNA library constructed from PBMC mRNA taken from an autoimmune patient (index patient) with systemic lupus erythematosus (SLE) (7–10). The cDNA library was screened with the patient’s own autoimmune serum which contained predominantly Abs to the autoantigen La/SS-B. During screening of the patient’s cDNA library, we identified a mutant La cDNA. Genomic DNA analysis of serial blood drawings of the index patient shows that the mutation persists for more than a decade (M. P. Bachmann, unpublished data). The mutation occurred in a region sensitive for mutations and can be found in >15% of anti-La positive autoimmune patients (I. Semsei, unpublished observation).

Native La protein is thought to be involved in essential housekeeping functions. These functions include a role in transcription/termination of RNA synthesized by polymerase III, 3′-RNA processing, and nuclear RNA import and retention (11–17). Furthermore, this autoantigen may participate in stabilization of mRNAs and translation of viral and mitogen-stimulated mRNAs (18–29). e.g., La protein was shown to be involved in the cap-independent translation of the mRNAs encoding the X-linked inhibitor of apoptosis and the double minute gene product mdm2 which is a regulator of the stability of p53 (30–32). Thus, an impaired expression of La protein could even have a direct effect on
the survival of autoreactive cells and could, thereby, contribute to the development of autoimmunity.

Due to the presence of the PTC in the mutant La mRNA, however, the mutant La mRNA should be eliminated by the NMD mechanism and should not be translated to protein. Consequently, it should not become a target of an immune response. However, in this study, we report that the serum of this patient and ~30% of anti-La-positive sera of SLE patients in general contain Abs to a mutant La-specific neoepitope suggesting that mutant La mRNAs were transcribed in these patients, circumvented NMD, were translated to protein, and became a target of an immune response. To analyze how mutant La mRNAs escape NMD, we established mice transgenic for the mutant form of La. We show that mutant La mRNAs are not only repressed and translated to mutant La protein, but, unexpectedly, expression of mutant La favors the development of systemic autoimmunity.

Materials and Methods

Patient sera and mAbs

The serum samples from patients with SLE or primary Sjögren’s syndrome-positive for IgG Abs to La protein were obtained from a routine autoantibody testing laboratory (Institute of Immunology, University of Dresden, Dresden, Germany). In addition, we used serum samples from mothers of children with either cardiac or cutaneous manifestations of neonatal lupus (ages 20–50 years) that were obtained from the Research Registry for neonatal lupus (35). The sera which were originally characterized as La positive by commercial routine ELISAs and immunoblotting were re-evaluated by ELISA and immunoblotting using recombinantly expressed human La protein (see also Proeinms and immunomasays). Age- and sex-matched control sera from healthy individuals and anti-La-negative sera from patients with SLE or scleroderma were acquired from the Oklahoma Medical Research Foundation (OMRF) Serum Repository and approved the use of all specimens in compliance with National Institutes of Health guidelines. As mAbs, we used the anti-La mAbs SW5, 4B6, and 3B9. SW5 is a well-established anti-La mAb which recognizes the N-domain of human La protein but not mouse La protein (15). The anti-La mAb 4B6 was described previously and shown to be directed to the C-domain of human La (34). The anti-La mAb 3B9 was established previously in our lab and recognizes both human and mouse La protein (M. P. Bachmann, unpublished data).

Mice

We housed all mice in specific pathogen-free conditions, and the OMRF Institutional Animal Care and Use Committee approved all mouse-related studies. Mice transgenic for the wild-type human La gene including its natural promoter have been described (35), and we used them as heterozygous at the gF32 backcross generation. We genotyped these mice as previously described (36). Mutant La-transgenic mice were generated as follows. We initiated the creation of the mutant La transgene with a construct containing the native human La gene that we had also used to establish the mouse 3T3 cell line expressing native human La (8). First, we deleted an AvrII fragment from the native La genomic clone. The remaining construct contained a unique HphI site in exon 3 and a unique BstEI site in exon 10 of La. We replaced the KpnI/BstEI fragment from this genomic native La construct with the respective mutant La cDNA fragment and then restored the AvrII fragment in the AvrII site. To prepare linearized DNA that was devoid of a bacterially derived sequence for FVB/N-fertilized oocyte injection, we released the mutant La gene from the vector with XhoI. We identified four positive FVB/N founder mice (one male and three females) by PCR using primers specific for the mutant La cDNA fragment and crossed them with FVB/N mice obtained from The Jackson Laboratory. The male founder was used to establish the mouse strain M1. Two of the female mice did not transfer the transgene to their offspring. The remaining female founder produced a single positive F1 mouse. This mouse was used to establish the mouse strain M2. We checked the presence of the transgene by PCR using three primer pairs. The primer pairs were specific for regions either inside or at the 5‘- or 3‘-end of the human La gene (data not shown). We confirmed the presence of the transgene by Southern blotting (data not shown) and, ultimately, by analysis of protein expression.

Immunostaining and confocal microscopy

For immunohistochemistry, tissue samples (~0.25 cm2) were extracted from mice following CO2 anesthesia, fixed overnight in chilled 2% paraformaldehyde in PBS, then allowed to equilibrate in 30% sucrose at 4°C. Sucrose-infiltrated samples were cryopreserved in Tissue Freezing Medium (Triangle Biomedical Sciences) and 5-μm serial sections were cut and placed on positively charged slides. Slides were allowed to come to room temperature, then sections were treated 30 min with 0.3% hydrogen peroxide to block endogenous peroxidase activity. Sections were stained using the Histomouse SP DAB staining kit (Zymed Laboratories) according to manufacturer’s suggested guidelines. Briefly, sections were blocked for 40 min with BEAT blocking reagent, then rinsed with water and PBS. Either PBS or a 1/50 dilution of the anti-human La Ab SW5 was added to the sections and incubated at room temperature in a humidified chamber for 1 h. After rinsing with PBS, sections were incubated for 10 min with biotinylated enzyme conjugate, developed with the substrate-chromagen mixture for 5 min, and rinsed with distilled water. Slides were counterstained with hematoxylin for 1 min, rinsed thoroughly in tap water followed by 30 s in PBS then distilled water. Sections were dehydrated through a graded alcohol series and three changes of xylene and cover-slipped. Slides were evaluated on the Zeiss Axiosplan 2I light microscope (Carl Zeiss Microimaging) at ×63 and ×100 magnifications and photodocumented.

For detection of immune complexes in kidney sections, kidneys were fixed in chilled 2% paraformaldehyde in PBS and equilibrated in 30% sucrose in PBS before cryopreservation. We then blocked 5-μm sections with 5% powdered milk in PBS and subsequently stained with optimized dilutions of primary conjugates of Alexa Fluor 546 rabbit anti-mouse IgG (H + L) (Molecular Probes) and goat anti-mouse complement C3-FITC (ICN-Cappel) in PBS. We rinsed the samples twice with PBS containing 0.1% Triton X-100, twice with PBS alone, then incubated with an optimized dilution of 6-×-diluted Alexa Fluor 647-phalloidin (Molecular Probes) and stained for 1 h. After rinsing with PBS, sections were incubated for 10 min with biotinylated enzyme conjugate, developed with the substrate-chromagen mixture for 5 min, and rinsed with distilled water. Slides were counterstained with hematoxylin for 1 min, rinsed thoroughly in tap water followed by 30 s in PBS then distilled water. Sections were dehydrated through a graded alcohol series and three changes of xylene and cover-slipped.

Proteins and immunomasays

For immunohistochemistry, tissue samples (~0.25 cm2) were extracted from mice following CO2 anesthesia, fixed overnight in chilled 2% paraformaldehyde in PBS, then allowed to equilibrate in 30% sucrose at 4°C. Sucrose-infiltrated samples were cryopreserved in Tissue Freezing Medium (Triangle Biomedical Sciences) and 5-μm serial sections were cut and placed on positively charged slides. Slides were allowed to come to room temperature, then sections were treated 30 min with 0.3% hydrogen peroxide to block endogenous peroxidase activity. Sections were stained using the Histomouse SP DAB staining kit (Zymed Laboratories) according to manufacturer’s suggested guidelines. Briefly, sections were blocked for 40 min with BEAT blocking reagent, then rinsed with water and PBS. Either PBS or a 1/50 dilution of the anti-human La Ab SW5 was added to the sections and incubated at room temperature in a humidified chamber for 1 h. After rinsing with PBS, sections were incubated for 10 min with biotinylated enzyme conjugate, developed with the substrate-chromagen mixture for 5 min, and rinsed with distilled water. Slides were counterstained with hematoxylin for 1 min, rinsed thoroughly in tap water followed by 30 s in PBS then distilled water. Sections were dehydrated through a graded alcohol series and three changes of xylene and cover-slipped. Slides were evaluated on the Zeiss Axiosplan 2I light microscope (Carl Zeiss Microimaging) at ×63 and ×100 magnifications and photodocumented.

For detection of immune complexes in kidney sections, kidneys were fixed in chilled 2% paraformaldehyde in PBS and equilibrated in 30% sucrose in PBS before cryopreservation. We then blocked 5-μm sections with 5% powdered milk in PBS and subsequently stained with optimized dilutions of primary conjugates of Alexa Fluor 546 rabbit anti-mouse IgG (H + L) (Molecular Probes) and goat anti-mouse complement C3-FITC (ICN-Cappel) in PBS. We rinsed the samples twice with PBS containing 0.1% Triton X-100, twice with PBS alone, then incubated with an optimized dilution of 6-×-diluted Alexa Fluor 647-phalloidin (Molecular Probes) and stained for 1 h. After rinsing with PBS, sections were incubated for 10 min with biotinylated enzyme conjugate, developed with the substrate-chromagen mixture for 5 min, and rinsed with distilled water. Slides were counterstained with hematoxylin for 1 min, rinsed thoroughly in tap water followed by 30 s in PBS then distilled water. Sections were dehydrated through a graded alcohol series and three changes of xylene and cover-slipped.

Immunoprecipitation and SDS-PAGE/immunoblotting

For immunoprecipitation of total extracts, we used the immunoprecipitation system from NatuTec. Immunoprecipitated proteins were subjected to SDS-PAGE immunoblotting. The NatuTec system uses a secondary anti-mouse Ab which is directed to a conformational epitope that is destroyed...
under reducing conditions. Consequently, heating of the immunoprecipitated material before electrophoresis under reducing conditions destroys the ability to detect coprecipitated mouse IgGs. Blots were qualitatively and quantitatively evaluated using the ECL system (Amersham Biosciences) and the CHEMI DOC XRS system (Bio-Rad).

Quantitative RT-PCR

The expression of human exon 1, exon1’, 1’, mouse exon 1a,b,c La mRNA, and actin mRNA was analyzed by a light cycler-based PCR assay. The relative mRNA quantity was determined applying a real-time PCR protocol based on SYBR Green I detection (LC-FastStart DNA Master SYBR Green I; Roche Diagnostics). Serial dilutions of plasmid DNA containing the respective specific human or mouse La mRNA or actin fragment over seven log scales (10^{-10}–10^9 molecules/capillary) were used as internal template standards (calculation via LC quantification software version 3.5; Roche Diagnostics). Each determination was conducted twice for each cDNA sample as independent PCR runs. The mean values for the La mRNA forms were normalized to the actin control. The assays were first established on normalized commercial human (I, II, fetal, and blood fractions) and mouse cDNA panels (I and II; all from BD Biosciences/BD Clontech). After subcloning of the PCR products in pGEM-Teasy, the specificity of the PCRs was determined by sequencing. Finally, mRNAs were isolated from shock-frozen tissues of native human La-, mutant human La-, and nontransgenic mice. mRNA isolation and cDNA synthesis were performed as described previously (15). As forward primer, we used for amplification of human exon 1 La (5'–GAGGTCTGGTCTGGTCT GTTTTGTT, human exon 1’ La (5'–GGGGAAGCCGCGGAGGGTTTC), mouse exon 1a,b La (5'–GAGAAGTCACGGCGCTTCTGTCG), mouse exon 1c La (5'–GGGAAACCTGTAAGGT TAGGAATTC), and actin (5'–GGGAGTCGTTGCTGCTGTTG) mRNA. As reverse primer, we used for amplification of human exon 1 and 1 La (5'–CAGTGCTTCTCCCTCCTCATGTCG) and, actin (5'–GGAGCCACACGCAGCTCATTG TGGTGATCTT) mRNAs. As reverse primer, we used for amplification of human exon 1 and 1 La (5'–CAGTGCTTCTCCCTCCTCATGTCG), mouse exon 1a,b,c La (5’–GGAGTGTTGGTCT TTGTTG), and actin (5’–GGAGCCACACGCAGCTCATTG TGGTGATCTT), and, actin (5’–GGAGCCACACGCAGCTCATTG TGGTGATCTT) mRNAs. The PCR protocol consisted of a predenaturation step (10 min at 95°C) and 40 amplification cycles (15 s at 95°C for all samples; for human exon 1 La, 5 s at 74°C; for human exon 1’ La and actin mRNA; 5 s at 70°C, for mouse exon 1a,b La mRNA; 5 s at 68°C; for mouse exon 1c La mRNA; 5 s at 64°C; 14 s at 72°C for all samples).

Results

Mammalian La proteins consist of two domains (Fig. 1a). The N-domain binds to small RNAs. The C-domain contains the nuclear localization signal (NLS). In human La, the peptide which connects the two domains is encoded by exon 7. Within exon 7, the La sequence contains an oligo(A)3-region (Fig. 1b, nLa, nt 1051–1059) which encodes the aa 190–192 (Fig. 1b, nLa, amino acid KKN). The previously isolated mutant La cDNA has a deletion of one (A)-residue in the oligo(A)8-region (Fig. 1b, nLa). The resulting mutant protein reading frame is truncated and lacks the NLS. Consequently, the native 29-kDa form of the N-domain of La (Fig. 2a, lane 4) was taken 6 mo, the third sample (Fig. 2a, lane 6) 1 year, after the first drawing (Fig. 2a, lane 1). The anti-La response in this patient.

Detection of Abs to a neoepitope in mutant La in sera of anti-La-positive autoimmune patients

As mentioned above, downstream of the mutation, the mutant La amino acid sequence MKKENKIKWKLN (Fig. 1b, mLa, aa 193–204) differs from the native La amino acid sequence EERKQNKVEAK (Fig. 1b, nLa, aa 193–203). Full-length La protein, the native 29-kDa form of the N-domain of La (Fig. 2c, LaN; aa 1–203), the mutant form of the N-domain of La (Fig. 2c, mLaNNeo; aa 1–204), and the native 25-kDa C-domain of La (Fig. 2a, LaC; aa 204–408) were recombinantly expressed and blotted against serum samples from either healthy donors (50 samples) or anti-La-negative (25 samples) or anti-La-positive autoimmune patients (100 samples). The respective anti-La Abs were visualized with anti-human IgG specific secondary Abs which did not cross-react with human IgM Abs. Approximately 15% of the anti-La-positive sera reacted with LaN-Neo but not with LaN, suggesting a specific reactivity to the La neoepitope in these serum samples. One example is shown in Fig. 2a (lane 4). In addition to the anti-LaN-Neo reactivity, some sera reacted with the C-domain of La (e.g., in Fig. 2a, lane 9). Of most interest are the results obtained for the serum samples shown in Fig. 2a (lanes 4–6). These serum samples represent serial drawings from the same patient. The second sample (Fig. 2a, lane 5) was taken 6 mo, the third sample (Fig. 2a, lane 6) 1 year, after the first drawing (Fig. 2a, lane 4). These immunoblotting data show that the anti-mutant La response preceded the anti-La response in this patient.

FIGURE 1. Native (nLa) and mutant human La (muLa) protein (a and b). a, nLa consists of two domains. The C-domain contains a NLS. muLa contains a frame shift mutation (X). The resulting mutant protein reading frame is truncated and lacks the NLS. b, The native La mRNA (nLa) contains eight (A) residues at position 1051–1058. The deletion of one (A)-residue (muLa, arrow) results in a PTC (nt 1092–1094). Thus, the mutant La mRNA encodes a mutant reading frame (muLa) which differs from the nLa reading frame (nLa) downstream of the frame shift mutation (double-headed arrow). The mutant aa sequence is underlined. * The location of the PTC (c, 1 and 2). According to recent models, mRNAs containing a PTC are recognized and eliminated by NMD as EJCIs will remain associated with the mRNA after the first round of translation. As schematically shown in 1, the native human La mRNA consists of 12 exons. Consequently, 11 splice junctions will be formed during splicing. Four of these junctions locate downstream of the PTC (c2). Consequently, these four EJCIs should remain associated with the mutant La mRNA after the first round of translation and, thus, the mutant La mRNA should be recognized and destroyed by NMD.
LaHis, anti-La(b sera (Fig. 2/H11001 (FAKKEK QNKVEAK). We analyzed 109 anti-La-positive is underlined) and the corresponding native La peptide NatLa, NeoLa peptide (AKKMKKENKIKWKLN, the mutant La portion signed a series of overlapping synthetic peptides including the peptide ELISA specific for mutant La. For this purpose, we de-

this disadvantage of the immunoblotting assay, we developed a peptide ELISA specific for mutant La. For this purpose, we designed a series of overlapping synthetic peptides including the NeoLa peptide (AKKMKKENKIKWKLN, the mutant La portion is underlined) and the corresponding native La peptide NatLa (FAKKEKQNKVEAK). We analyzed 109 anti-La-positive sera (Fig. 2b, LaHis, anti-La(+) at dilutions of 1/1000 for Abs to the NeoLa (Fig. 2c, Neoepitope, anti-La(+) ) and NatLa peptide (data not shown). Thirty-one sera reacted with the NeoLa peptide at levels >4 SDs above the mean. In contrast, only two (n = 74) of control negative sera were positive. Our negative control group consisted of anti-La-negative SLE patients (n = 52, 20 sera were anti-Ro only), patients with scleroderma (n = 7) and healthy blood donors (n = 15). None of the sera reacted with the NatLa peptide although it contained the three amino acid AKK that were also part of the NeoLa peptide. To confirm the specificity of the anti-NeoLa peptide reactivity, we adsorbed anti-NeoLa-positive sera with the recombinantly expressed mutant La protein which completely blocked the anti-NeoLa reactivity (data not shown). In contrast, the recombinantly expressed N-domain of La lacking the NeoLa sequence was not able to block the anti-NeoLa peptide reactivity. Moreover, NeoLa-positive sera were negative when analyzed on peptides representing the scrambled NeoLa amino acid sequence (data not shown).

Taken together, our data show that 1) a mutant La response can precede an anti-La response, 2) Abs to mutant La can be detected in ~30% of anti-La-positive autoimmune patients, and 3) mutant La can become a target of an immune response.

Development of two independent mouse lines transgenic for a mutant human La gene

The expression of mutant La protein requires that mutant La mRNA is capable of escaping NMD. To provide experimental evidence for an escape of mutant La mRNA from NMD, we established mice transgenic for mutant human La. The genomic construct encoding mutant human La was cloned as schematically summarized in Fig. 3a and described in detail in Materials and Methods. In summary, we replaced a KpnI/BstEII fragment in a reconstructed human La gene clone with the respective KpnI/BstEII fragment from a mutant La cDNA clone. The mutant exon7 was part of this KpnI/BstEII fragment.

It is obvious that the cloning procedure altered the number of splice sites in the resulting mutant La gene construct. Nonetheless, two splice sites were conserved downstream of the PTC and, thus, the encoded mRNA should still be recognized by NMD as schematically shown in Fig. 3b.

Two independent transgenic mouse lines (M1 and M2) were established from the mutant La gene construct (Fig. 3a). The integration of the transgene was detected by PCR and Southern blotting (data not shown).

Analysis of expression of mutant La at the RNA level in mutant La-transgenic mice

Real-time PCR assays were established allowing us to measure the copy numbers of human and mouse La mRNAs. In previous studies, we had shown that three La mRNA isoforms can be transcribed from the human La gene which we termed exon 1, exon 1’, and exon 1” La mRNAs. Comparable studies were not available for the mouse La gene. Therefore, we analyzed the expression of the mouse La gene (M. P. Bachmann, unpublished data). From these studies, we know that three mouse La mRNA isoforms exist. We termed these isoforms exon 1 a, b, and c. Like all the human La mRNA isoforms, all the murine La mRNAs are also functional. Despite their different 5’ starts, all La mRNAs encode the same human or mouse La protein, as the initiation codon locates in the exon 2.

Quantitative PCR was performed for RNAs isolated from tissues of either mutant La-transgenic (Fig. 4, a, M1, M2, and b, mLa), or nontransgenic (Fig. 4b, non-ig), or native La-transgenic mice (Fig. 4b, nLa). In addition, we estimated the copy number of La mRNAs for commercially available multilissue-cDNA panels (MTC) from mouse (Fig. 4b, mMTC) and human (Fig. 4b, hMTC) tissues. We analyzed a total of eight mutant La-transgenic mice, four native La-transgenic mice, and four nontransgenic FVB mice. RNAs were obtained from brain, liver, spleen, gut, and kidney. In addition, we analyzed the RNAs from thymus tissue when available. Results for liver and spleen tissues are shown in Fig. 4. Fig. 4a shows the data for individual animals. Fig. 4b gives the mean

FIGURE 3. (A) Predominantly mutant La mRNA expression in mutant La-transgenic mice. A) Sequence of the mutant mRNA construct. The native mRNA (NatLa) and the mutant mRNA (MutLa) are illustrated. B) mRNA expression in the La-transgenic mice. C) Schematic representation of the cloned mutant La construct (MTC) and wild-type La construct (WTC) (A1/A2, A3). D) Expression of murine La mRNA at the RNA level in different tissues of control and mutant La-transgenic mice. E) Schematic representation of the mutant La mRNA construct with the respective restriction enzymes (KpnI, BstEII). F) Expression of murine La mRNA at the RNA level in different tissues of control and mutant La-transgenic mice (MTC).
values of all analyzed animals. Our data shows: 1) the mouse La mRNAs are expressed at similar levels in nontransgenic and transgenic animals, 2) the human La mRNAs in the transgenic mice are expressed in addition to the endogenous mouse La mRNAs, and 3) the expression level of the respective La transgene is comparable to the endogenous mouse La mRNA level. Consequently, 1) the expression of the respective transgene does not alter the expression of the mouse La gene and 2), the mutant La transgene is expressed at similar levels as the native La transgene. Thus, the mutant La mRNA escapes NMD.

FIGURE 3. Features of the mutant La transgene. a, The cloning of the mutant La transgene (La gene mutant) started from a native human La transgene construct (La gene native). We replaced the genomic region from exons 2 to 10 of the human native La transgene with the respective sequence of a mutant La cDNA (mutant exon 1La cDNA). For this purpose, we isolated the KpnI/BsTElI fragment from the mutant exon 1 La cDNA construct and inserted it in the respective sites of the native La transgene. b, 1 and 2. Thereby, we conserved the introns upstream and downstream of the cDNA inserts. A mutant La mRNA transcribed and processed from this construct contains four splice junctions (1–4). Two splice junctions locate upstream and two downstream of the PTC. During the first round of translation, the scanning ribosome should not pass the exon junctions 3 and 4. Consequently, two EJCs should persist downstream of the PTC and the mutant La mRNA should be recognized and eliminated by NMD.

FIGURE 4. Quantitative analysis of expression of mutant La mRNA in mutant La-transgenic mice. Quantitative PCR was performed for RNAs isolated from liver (a) or spleen (b) tissues of either mutant La-transgenic (a, M1, M2; b, muLa), or nontransgenic (b, non-tg), or native La-transgenic mice (b, nLa). In addition, we estimated the copy number of La mRNAs for commercial MTC from mouse (b, mMTC) and human (b, hMTC). We estimated the copy numbers for mouse exon 1a and b La (blue bars), mouse exon 1c La (purple bars), human exon 1 La (brown bars), and human exon 1′,1″ La (yellow bars) mRNAs. The copy numbers were normalized to actin. a, The data for liver tissues of six individual animals. The estimations were performed at least as duplicates. The error bars show the deviation of the values. b, The data for spleen tissues. The mean values and the SDs of all analyzed animals are given. Similar results were obtained for other tissues.

Analysis of expression of mutant La in extracts from tissues of mutant La-transgenic mice

Using the anti-human La-specific mAb SW5, we detected the truncated human La protein in total tissue extracts of both mutant La-transgenic mouse lines M1 and M2 (Fig. 5a, muLa-tg, M1, and M2). To compare the expression levels, extracts of mutant La-transgenic mice (Fig. 5a, muLa-tg) and nontransgenic mice (Fig. 5a, non-tg) were normalized with anti-actin Abs. For some total tissue extracts, the detection of the mutant La transgene was difficult because of a high content of mouse Igs in these extracts which cross-reacted with the secondary Abs (data not shown). To improve the quality of the immunoblots and to allow a quantitative comparison of the mutant La protein expression in different tissues, we immunoprecipitated the extracts with the anti-human La-specific mAb SW5 and detected the immunoprecipitated Ag with
FIGURE 5. Expression of mutant La protein in transgenic mice. a, Extracts from mutant La transgenic mice (muLa-tg; M1,M2) and nontransgenic mice (non-tg) were prepared from spleen tissues and analyzed by SDS-PAGE/immunoblotting with the anti-La mAb SW5 which recognizes the N-domain of human La. The extracts were normalized with anti-actin Abs. b, Extracts from different tissues of mutant La-transgenic mice (muLa-tg) were prepared from thymus, spleen, liver, brain, kidney, and intestine, immunoprecipitated with the anti-La mAb SW5 and analyzed by SDS-PAGE/immunoblotting with the anti-La mAb SW5 which recognizes the N-domain of human La and therefore also reacts with mutant human La (muLa). c, Tissues from mice transgenic for mutant La (muLa-tg) or native La (nLa-tg) or from nontransgenic mice (non-tg) were stained with the human anti-La specific mAb SW5 (see Materials and Methods). Due to the lack of the NLS, mutant La (muLa-tg, SW5) is in the cytoplasm while native La (nLa-tg, SW5) is in the nucleus. SW5 does not stain tissues from nontransgenic mice irrespective of the background (FVB/N or B6). The negative controls (negative) were also not stained.

FIGURE 6. Expression of full-length human La in mutant La-transgenic mice. Total extracts from liver tissue of mice either transgenic for mutant La (lanes a–d), or native La (lanes e, g, and i), or nontransgenic (lanes f, h, and j) were immunoprecipitated with an anti-La serum and blotted against the anti-La mAbs 3B9 (lanes a, e, and f), SW5 (lanes b, g, and h), and 4B6 (lanes c, i, and j). The anti-La mAb 3B9 recognizes human and mouse La protein. In contrast, the anti-La mAbs SW5 and 4B6 do not cross-react with mouse La protein. The epitopes recognized by SW5 and 3B9 locate in the N-domain of La while the epitope recognized by 4B6 locates in the C-domain. A mixture of unrelated mAbs did not react with any immunoprecipitated protein (lane d). hLa, human La; moLa, mouse La; muLa, mutant La.

a secondary Ab which does not bind to reduced Igs (see Materials and Methods). As shown in Fig. 5b, the mutant La protein was equally expressed in all organs tested including in thymus, spleen, liver, brain, kidney, and intestine (Fig. 5b, muLa).

Intracellular localization of mutant La in tissues of mutant La-transgenic mice

When tissues were stained with the anti-human La-specific anti-La mAb SW5, the mutant protein which lacks the NLS was found in the cytoplasm (Fig. 5c, muLa-tg) while the native La transgene was found in the nucleus (Fig. 5c, nLa-tg).

Detection of native human La in extracts from tissues of mutant La-transgenic mice

Extracts from tissues of mutant La-transgenic (Fig. 6, a–d), native La-transgenic (Fig. 6, lanes e, g, and i), and nontransgenic (Fig. 6, lanes f, h, and j) mice were precipitated with an anti-human La serum. The precipitated La peptides were analyzed with the anti-La mAbs 3B9 (Fig. 6, lanes a, e, and f), SW5 (Fig. 6, lanes b, g, and h), and 4B6 (Fig. 6, lane c, i, and j). The anti-La mAb 3B9, which recognizes the N-domain of both human and mouse La protein, reacted with the endogenous mouse La protein in all analyzed transgenic and nontransgenic extract samples (Fig. 6, lanes a, e, and f). In addition, it reacted with the mutant human La protein in the extract of the mutant La-transgenic mouse (Fig. 6, lane a) and the native human La protein in the extract of the native La-transgenic mouse (Fig. 6, lane e). The human anti-La-specific mAb SW5, which is directed to the N-domain of human La, also reacted with the mutant human La protein (Fig. 6, lane b) and the native human La protein (Fig. 6, lane g) but failed to react with the endogenous mouse La protein (e.g., Fig. 6, lane h). The anti-human La-specific anti-La mAb 4B6, which is directed to the C-domain of human La, also reacted with the native human La protein in the extract of the native La-transgenic mouse (Fig. 6, lane i). However, it failed to react with the mutant human La protein (Fig. 6, lane c) and the endogenous mouse La protein (e.g., Fig. 6, lane j). Unexpectedly, all three monoclonal anti-La Abs reacted with an additional protein in the extract of the mutant La-transgenic mice (Fig. 6, lanes a–c). This protein, which has the same molecular weight as full-length human La protein, is absent in the extract of the nontransgenic mouse (Fig. 6, lanes f, h, and j). Taken together, the protein 1) has the same molecular weight as human La protein, 2) is coprecipitated by the anti-La serum, and 3) is recognized by three anti-La mAbs. From previous studies, we know that the three anti-La mAbs recognize independent epitopes. The two epitopes recognized by the anti-La mAbs 3B9, and SW5 are upstream of the frame shift mutation. The epitope recognized by the anti-La mAb 4B6 is downstream of the frame shift mutation. Therefore, we conclude that this protein represents full-length human La protein. Full-length human La protein can only be translated from the mutant La mRNA if ribosomal frame shifting occurs upstream of the PTC.
Systemic autoimmunity in mice transgenic for mutant human La

As mentioned above, during the immunoblotting experiments, we detected high levels of Igs in extracts from tissues of older mutant La-transgenic mice, especially in kidney tissue extracts. Similar results were not seen for age-matched FVB/N controls (data not shown). Clinical SLE is characterized by the presence of antinuclear autoantibodies (ANA) and immune complex deposits in tissues.

Immune complex nephritis in mice transgenic for mutant human La. Therefore, we checked mutant La-transgenic mice for proteinuria and analyzed kidney tissues of mutant La-transgenic mice for Ab deposits. Six of ten animals showed mild to moderate proteinuria. Two animals had severe proteinuria (+ + +). Tissues from these animals were further analyzed. Their histology data are shown in Fig. 7. We detected glomeruli which were positively stained with Abs to Ig and complement (Fig. 7, a–g). Similar deposits were not seen in age-matched FVB/N controls (Fig. 7, h–j).

Spontaneous development of autoantibodies. The histology data suggested the development of autoantibodies in mutant La-transgenic mice. We analyzed 58 serum samples taken from 42 mutant La-transgenic mice for Ab deposits. Six of ten animals showed mild to moderate proteinuria. Two animals had severe proteinuria (+ + +). Tissues from these animals were further analyzed. Their histology data are shown in Fig. 7. We detected glomeruli which were positively stained with Abs to Ig and complement (Fig. 7, a–g). Similar deposits were not seen in age-matched FVB/N controls (Fig. 7, h–j).

Spontaneous development of autoantibodies. We analyzed 58 serum samples taken from 42 mutant La-transgenic mice for Ab deposits. Six of ten animals showed mild to moderate proteinuria. Two animals had severe proteinuria (+ + +). Tissues from these animals were further analyzed. Their histology data are shown in Fig. 7. We detected glomeruli which were positively stained with Abs to Ig and complement (Fig. 7, a–g). Similar deposits were not seen in age-matched FVB/N controls (Fig. 7, h–j).

Immune complex nephritis in mice transgenic for mutant human La. Therefore, we checked mutant La-transgenic mice for proteinuria and analyzed kidney tissues of mutant La-transgenic mice for Ab deposits. Six of ten animals showed mild to moderate proteinuria. Two animals had severe proteinuria (+ + +). Tissues from these animals were further analyzed. Their histology data are shown in Fig. 7. We detected glomeruli which were positively stained with Abs to Ig and complement (Fig. 7, a–g). Similar deposits were not seen in age-matched FVB/N controls (Fig. 7, h–j).

Spontaneous development of autoantibodies. The histology data suggested the development of autoantibodies in mutant La-transgenic mice. We analyzed 58 serum samples taken from 42 mutant La-transgenic mice for Ab deposits. Six of ten animals showed mild to moderate proteinuria. Two animals had severe proteinuria (+ + +). Tissues from these animals were further analyzed. Their histology data are shown in Fig. 7. We detected glomeruli which were positively stained with Abs to Ig and complement (Fig. 7, a–g). Similar deposits were not seen in age-matched FVB/N controls (Fig. 7, h–j).

FIGURE 7. Immune complex deposition in kidneys of mutant La-transgenic mice. We stained kidney sections from mice transgenic for mutant La (a–g) and FVB/N control animals (h–j) with anti-Ig Ab (red), anti-complement Ab (green), and DAPI (blue). a, Three-color overlay of a nephron of a mouse transgenic for mutant La. b–g, Glomeruli from mice transgenic for mutant La. h–j, FVB/N controls.
In accord with this reasoning, we expected that the identified frame shift mutation in the patient’s La cDNA should not result in an immune response. However, we detected anti-NeoLa Abs in the serum of this patient and even more surprising in 30% of all analyzed anti-La-positive autoimmune patients. Anti-NeoLa Abs were detected with two independent techniques. Using the immunoblotting technique, one cannot identify anti-NeoLa Abs in serum samples which react with the native N-domain of La protein. Consequently, the immunoblotting technique results in an underestimation of the anti-NeoLa frequency. However, the ELISA specific for the NeoLa peptide allowed us to overcome this limitation.

At present, we do not know whether the occurrence of the mutant La was the event for triggering of the anti-NeoLa immune response in the autoimmune patient(s) or the mutant La epitope became a target of an (auto)immune response because it was expressed just at the time when the immune response occurred. At least in the mutant La-transgenic mice, which should be tolerant to the mutant La form, the latter mechanism seems to work. In

**FIGURE 8.** Autoantibodies in mice transgenic for mutant La. *a* and *b*, Development of autoantibodies in mice transgenic for mutant La. We analyzed sera from the mutant La-transgenic mouse lines M1 and M2 for Abs to neoLa, La, Ro, and dsDNA. The dashed lines represent cutoffs for positive reaction based on mean plus four SDs of 15 control FVB/N antisera. Nine of the control mice were 5–6 mo of age. Six mice were older than 7 mo. *c–f*, Ab pattern of individual mice. The autoantibody pattern differs between individual mice. Some mice develop Abs to NeoLa, La, Ro, and dsDNA (e.g., *c*), others Abs to NeoLa and La but not to Ro and dsDNA (e.g., *d*), or to NeoLa, La and Ro but not to dsDNA (e.g., *e*). In some mice the response started with anti-Ro Abs (e.g., *e*) in others with anti-Sm Abs (*f*). The serum samples (1–4) in *f* were taken at the age of 4–8 mo. *g*, One of the analyzed mice was positive for ANAs in immunofluorescence but negative in ELISA for Sm, RNP, Ro, La, dsDNA. *h*, FVB/N negative control. *i*, Secondary Ab control.
patients who express the mutant La epitope after establishing tolerance, both possibilities or a combination of them could also be considered.

Either way, the development of an IgG type anti-NeoLa response requires the expression of mutant La or a mutant La-related epitope at the time when the immune response started. One prerequisite for the expression of mutant La protein, however, is an escape of the mutant La mRNA from RNA control. In a previous study, we had shown that Escherichia coli and insect cells can partially correct the mutant La-reading frame by ribosomal frame shifting. Ribosomal frame shifting most likely occurs in the oligo(A)-region upstream of the PTC in exon7 (34). Due to this, ribosomal frame-shifting expression of the mutant La mRNA does not only result in the expression of the prematurely terminated truncated form of La. In addition to the mutant La protein, a portion of correct human La was made. However, whether this ribosomal frame shifting could also occur in mammalian cells was unclear. If so, the ribosomes translating the mutant La mRNA have to slip into the native La-reading frame. The shift has to occur upstream of the PTC and, thus, the ribosomes will bypass the PTC. During translation of the native reading frame downstream of the PTC, these ribosomes can pass all exon splice junctions downstream of the PTC in the mutant La mRNA and terminate translation at the native La mRNA stop codon. Thereby, all EJCs downstream of the PTC will be removed. Consequently, NMD cannot detect the frame shift mutation in the mutant La mRNA, and the mutant La mRNA will, thus, circumvent NMD.

To experimentally verify that mutant La mRNA can escape from NMD by ribosomal frame shifting, we established two independent mouse lines transgenic for mutant La. Southern blotting verified the integration of the respective transgene into independent genomic regions in these two lines of mice (data not shown). Quantitative PCR, immunoblotting analysis, and immunohistology show that the mutant La mRNA is not eliminated by NMD. In addition to mutant La, a protein is made which 1) has the same size as native human La protein, 2) was co-precipitated by patient anti-La Abs, and 3) reacted with three monoclonal anti-La Abs on immunoblots. The used anti-La Abs recognize unrelated epitopes in either the N- or the C-domain of La. Therefore, the anti-La-reactive protein contains La epitopes upstream and downstream of the PTC in the mutant La mRNA. This strongly supports the interpretation that ribosomal frame shifting upstream of the PTC in mutant La mRNA is not restricted to bacterial and insect cells but can also occur in mammalian cells.

In summary, the capability to correct the mutant La reading frame into the native La reading frame by ribosomal frame shifting may be the reason for escape of mutant La mRNAs from NMD.

Both mouse lines develop ANAs including to dsDNA and an immune complex nephritis. The observation of a lupus phenotype in both transgenic lines strongly argues that this phenotype is critically dependent upon the mutant La transgene itself. Thus, expression of mutant La seems to result in an increased risk for developing an autoimmune phenotype.

As La protein is hypothesized to be involved in so many different cellular functions, there are several possibilities as to how the expression of mutant La enhances the risk of an autoimmune response in the transgenic mice. For example, La protein was hypothesized to work as a RNA chaperone and to be involved in the correct folding of ribonucleoproteins (RNP) including for example in RNA quality control of SS ribosomal RNA. An impaired assembly of ribosomes and/or an increased rate of incorrectly folded RNPs could easily lead to neoepitopes which could become the target of an immune response. Alternatively, the mutant La protein could indirectly interfere with the apoptosis pathway allowing perhaps the survival of autoreactive T and B cells (31, 32).

Many recently described transgenic or knockout mice which interfere with the expression of components of the immune system or the apoptosis pathway develop autoimmune phenotypes (39). Although a direct link between La protein, apoptosis resistance, and the immune system has not yet been experimentally shown, there are reports supporting such a function. As mentioned in the introduction section La protein was shown to be involved in the cap-independent translation of the X-linked inhibitor of apoptosis. Moreover, La protein is involved in the translation of the mdm2 protein (21, 22). The mdm2 protein is a negative regulator of p53. p53 is a key regulator in DNA repair, the cell cycle and the apoptosis pathway, e.g., p53 is a transcription factor of the cell cycle inhibitor p21. Consequently, a down-regulation of mdm2 would result in an up-regulation of p21. Interestingly, p21 is known to be up-regulated in many experimental autoimmune animal models, and is assumed to stabilize autoreactive memory cells in SLE patients (35). Consequently, an altered expression of La protein could affect the apoptosis resistance and the survival of autoreactive immune cells. Indeed, preliminary data show that La-overexpressing cells have an increased apoptosis resistance while knocking down the expression of La increases the apoptosis sensitivity of cells (M. P. Bachmann, unpublished data). Furthermore, real-time PCR shows a 100-fold up-regulation of p21 including in lymphus in the mutant La-transgenic mice but not in control animals (M. P. Bachmann, unpublished data).

In summary, our data suggest that mutant La mRNAs can circumvent NMD most likely via ribosomal frame shifting. Expression of mutant La can have two effects: 1) it can become a target of an immune response in patients and mutant La-transgenic mice, and 2) it increases the risk of developing systemic autoimmunity, at least in mutant La-transgenic mice. The expression of mutant La may interfere with one or all of the functions of the La Ag which finally leads to a predisposition toward an autoimmune response. In contrast to the occurrence of autoimmunity in many other transgenic mice, the autoimmune response in the mutant La-transgenic mice may reflect a true risk factor in human SLE, as suggested by the escape mechanism described here and as suggested by the detection of Abs to the NeoLa form in a significant fraction of SLE patients.

Disclosures

The authors have no financial conflict of interest.

References

9. Grötz, D., H. Bartsch, H. Tröster, and M. Bachmann. 1997. The nuclear autoantigen La/SS-B: mapping and sequencing of the gene and the three retropseudo-


